Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line treatment. Although much is known about the pleiotrop...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2020-02-01
|
| Col·lecció: | Cells |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/2073-4409/9/2/378 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|